{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:42:20Z","timestamp":1788522140585,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ajt.2024.01.007","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T08:14:37Z","timestamp":1705824877000},"page":"1087-1090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-6295","authenticated-orcid":false,"given":"Pramod","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9060-741X","authenticated-orcid":false,"given":"Pradeep","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Nidoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.K.","family":"Adarsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashish","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mathangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sandhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Gopasetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ajt.2024.01.007_bib1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/lt.24782","article-title":"The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation","volume":"23","author":"Choi","year":"2017","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.ajt.2024.01.007_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"20","key":"10.1016\/j.ajt.2024.01.007_bib3","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.3390\/cancers14205102","article-title":"Downstaging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis on intention-to-treat outcomes","volume":"14","author":"Di Martino","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ajt.2024.01.007_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001304","article-title":"Immune checkpoint inhibitor therapy before liver transplantation-case and literature review","volume":"8","author":"Aby","year":"2022","journal-title":"Transplant Direct"},{"issue":"6","key":"10.1016\/j.ajt.2024.01.007_bib5","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/ajt.16965","article-title":"Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab","volume":"22","author":"Schnickel","year":"2022","journal-title":"Am J Transplant"},{"issue":"20","key":"10.1016\/j.ajt.2024.01.007_bib6","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ajt.2024.01.007_bib7","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1097\/TP.0000000000003162","article-title":"Experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis post downstaging","volume":"104","author":"Soin","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.ajt.2024.01.007_bib8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cjco.2020.11.004","article-title":"Plasma exchange for immune checkpoint inhibitor-induced myocarditis","volume":"3","author":"Yogasundaram","year":"2021","journal-title":"CJC open"},{"issue":"10","key":"10.1016\/j.ajt.2024.01.007_bib9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.4240\/wjgs.v13.i10.1267","article-title":"Immunotherapy after liver transplantation: where are we now?","volume":"13","author":"Au","year":"2021","journal-title":"World J Gastrointest Surg"},{"issue":"5","key":"10.1016\/j.ajt.2024.01.007_bib10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/lt.26416","article-title":"Preliminary evaluation of atezolizumab plus bevacizumab as salvage treatment for recurrent hepatocellular carcinoma after liver transplantation","volume":"28","author":"Yang","year":"2022","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.ajt.2024.01.007_bib11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.21037\/jgo-22-922","article-title":"Immune checkpoint inhibitors in liver transplant: a case series","volume":"14","author":"Rudolph","year":"2023","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"22","key":"10.1016\/j.ajt.2024.01.007_bib12","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.3748\/wjg.v27.i22.2994","article-title":"Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment","volume":"27","author":"Granito","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.ajt.2024.01.007_bib13","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3390\/cancers14092056","article-title":"Immune checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation","volume":"14","author":"Katariya","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ajt.2024.01.007_bib14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.transproceed.2023.03.064","article-title":"Optimizing the safe washout period for liver transplantation following immune checkpoint inhibitors with atezolizumab, nivolumab, or pembrolizumab","volume":"55","author":"Kuo","year":"2023","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.ajt.2024.01.007_bib15","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/ajt.16448","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am J Transplant"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613524000728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613524000728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T02:22:10Z","timestamp":1748744530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613524000728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1600613524000728"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2024.01.007","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2024.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}